Tag Archives: BioMarin

Analysts Are Bullish on These Healthcare Stocks: BioMarin (BMRN), ADMA Biologics (ADMA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin (BMRN – Research Report), ADMA Biologics (ADMA – Research Report) and Vertex Pharmaceuticals (VRTX – Research Report) with bullish sentiments. BioMarin

Analysts Offer Insights on Healthcare Companies: BioMarin (NASDAQ: BMRN) and Prothena Corp (NASDAQ: PRTA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin (BMRN – Research Report) and Prothena Corp (PRTA – Research Report) with bullish sentiments. BioMarin (BMRN) Cantor Fitzgerald analyst Eliana Merle

Barclays Remains a Hold on BioMarin (BMRN)

Barclays analyst Gena Wang maintained a Hold rating on BioMarin (BMRN – Research Report) on February 22 and set a price target of $95. The company’s shares closed on Friday at $87.87. According to TipRanks.com, Wang is a 5-star analyst

BioMarin (BMRN) Receives a Hold from Oppenheimer

Oppenheimer analyst Leland Gershell maintained a Hold rating on BioMarin (BMRN – Research Report) yesterday and set a price target of $92. The company’s shares closed yesterday at $93.76. Gershell wrote: “Three-year results from an ongoing open-label study presented yesterday

Analysts Offer Insights on Healthcare Companies: BioMarin (NASDAQ: BMRN), Alnylam Pharma (NASDAQ: ALNY) and Emergent Biosolutions (NYSE: EBS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioMarin (BMRN – Research Report), Alnylam Pharma (ALNY – Research Report) and Emergent Biosolutions (EBS – Research Report). BioMarin (BMRN) Cowen & Co.

Cantor Fitzgerald Sticks to Its Buy Rating for BioMarin (BMRN)

In a report released today, Eliana Merle from Cantor Fitzgerald maintained a Buy rating on BioMarin (BMRN – Research Report), with a price target of $126. The company’s shares opened today at $87.58. Merle said: “The Disclosure Section may be